WO2003061567A3 - Selective s1p1/edg1 receptor agonists - Google Patents

Selective s1p1/edg1 receptor agonists Download PDF

Info

Publication number
WO2003061567A3
WO2003061567A3 PCT/US2003/001120 US0301120W WO03061567A3 WO 2003061567 A3 WO2003061567 A3 WO 2003061567A3 US 0301120 W US0301120 W US 0301120W WO 03061567 A3 WO03061567 A3 WO 03061567A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
treating
edg1 receptor
compound
edg1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/001120
Other languages
French (fr)
Other versions
WO2003061567A2 (en
Inventor
George A Doherty
Michael J Forrest
Richard Hajdu
Jeffrey J Hale
Zhen Li
Suzanne M Mandala
Sander G Mills
Hugh Rosen
Edward M Scolnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to AU2003216054A priority Critical patent/AU2003216054B2/en
Priority to CA002472680A priority patent/CA2472680A1/en
Priority to EP20030731917 priority patent/EP1469863A2/en
Priority to US10/501,176 priority patent/US20050070506A1/en
Publication of WO2003061567A2 publication Critical patent/WO2003061567A2/en
Publication of WO2003061567A3 publication Critical patent/WO2003061567A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor, said compound administered in an amount effective for treating said immunoregulatory abnormality. Pharmaceutical compositions are included. The invention also encompasses a method of identifying candidate compounds that are agonists of the S1P1/Edg1 receptor and which possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor. The invention further encompasses a method of treating a respiratory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said respiratory disease or condition, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor.
PCT/US2003/001120 2002-01-18 2003-01-14 Selective s1p1/edg1 receptor agonists Ceased WO2003061567A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003216054A AU2003216054B2 (en) 2002-01-18 2003-01-14 Selective S1P1/Edg1 receptor agonists
CA002472680A CA2472680A1 (en) 2002-01-18 2003-01-14 Selective s1p1/edg1 receptor agonists
EP20030731917 EP1469863A2 (en) 2002-01-18 2003-01-14 Selective s1p1/edg1 receptor agonists
US10/501,176 US20050070506A1 (en) 2002-01-18 2003-01-14 Selective s1p1/edg1 receptor agonists

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US34999102P 2002-01-18 2002-01-18
US60/349,991 2002-01-18
US36256602P 2002-03-07 2002-03-07
US60/362,566 2002-03-07
US38293302P 2002-05-23 2002-05-23
US60/382,933 2002-05-23

Publications (2)

Publication Number Publication Date
WO2003061567A2 WO2003061567A2 (en) 2003-07-31
WO2003061567A3 true WO2003061567A3 (en) 2003-12-24

Family

ID=27617582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/001120 Ceased WO2003061567A2 (en) 2002-01-18 2003-01-14 Selective s1p1/edg1 receptor agonists

Country Status (5)

Country Link
US (1) US20050070506A1 (en)
EP (1) EP1469863A2 (en)
AU (1) AU2003216054B2 (en)
CA (1) CA2472680A1 (en)
WO (1) WO2003061567A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514419B2 (en) 2003-11-19 2009-04-07 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
US8415484B2 (en) 2008-08-27 2013-04-09 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
US8580841B2 (en) 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
US8853419B2 (en) 2010-01-27 2014-10-07 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1115396A4 (en) 1998-09-25 2002-05-22 Sunol Molecular Corp Pharmaceutically active compounds and methods of use thereof
JP2004529100A (en) 2001-01-30 2004-09-24 ユニバーシティ オブ バージニア パテント ファウンデーション Agonists and antagonists of sphingosine-1-phosphate receptor
ATE448193T1 (en) * 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATES, PHOSPHONATES AND TETRAZOLES AS EDG RECEPTOR AGONISTSß
US7241790B2 (en) 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
JP4571497B2 (en) 2002-09-19 2010-10-27 杏林製薬株式会社 Amino alcohol derivatives and their addition salts and immunosuppressants
DE60335827D1 (en) 2002-12-20 2011-03-03 Merck Sharp & Dohme 1- (AMINO) INDANE AS EDG RECEPTOR AGONISTS
BRPI0407658A (en) * 2003-02-18 2006-02-21 Kyorin Seiyaku Kk aminophosphonic acid derivatives, their salts and hydrates that act as s1p receptor modulators and pharmaceutical agent
PE20130200A1 (en) 2003-04-08 2013-03-09 Novartis Ag PHARMACEUTICAL COMPOSITION CONTAINING AN S1P RECEPTOR AGONIST AND A SUGAR ALCOHOL
CL2004001120A1 (en) 2003-05-19 2005-04-15 Irm Llc COMPOUNDS DERIVED FROM AMINA REPLACED WITH HETEROCICLES, IMMUNOSUPPRESSORS; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT DISEASES MEDIATED BY LYMPHOCYTE INTERACTIONS, SUCH AS AUTOIMMUNE, INFLAMMATORY, INFECTIOUS, CANCER DISEASES.
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
MXPA05012459A (en) 2003-05-19 2006-02-22 Irm Llc Immunosuppressant compounds and compositions.
PL1643983T3 (en) * 2003-06-24 2010-10-29 Univ Connecticut Methods of inhibiting vascular permeability and apoptosis
RU2390519C2 (en) * 2003-08-29 2010-05-27 Оно Фармасьютикал Ко., Лтд. Compound capable of bonding with s1p receptor and pharmaceutical application thereof
KR20110140139A (en) 2003-08-29 2011-12-30 오노 야꾸힝 고교 가부시키가이샤 Compound Having S1P Receptor Binding Ability and its Pharmaceutical Use
US7825109B2 (en) 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
GB0401332D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
AU2005237254B2 (en) 2004-05-03 2010-02-04 Novartis Ag Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
CA2572770A1 (en) 2004-07-08 2006-01-19 Novo-Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
MX2007001661A (en) 2004-08-13 2007-04-23 Praecis Pharm Inc Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity.
CA2583681A1 (en) * 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
PL1650186T3 (en) * 2004-10-22 2008-11-28 Bioprojet Soc Civ Novel dicarboxylic acid derivatives
KR20070085465A (en) 2004-11-29 2007-08-27 노파르티스 아게 Dosage of S1 receptor agonist
BRPI0519012A2 (en) * 2004-12-13 2008-12-23 Ono Pharmaceutical Co aminocarboxylic acid derivative and its medicinal use
CA2595960A1 (en) * 2005-02-08 2006-08-17 Novartis Ag Antilymphocyte antibody induction by combination of an s1p receptor agonist/modulator and of immunosuppressive drugs
US7754703B2 (en) 2005-02-14 2010-07-13 University Of Virginia Patent Foundation Cycloalkane-containing sphingosine 1-phosphate agonists
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
MX2007014502A (en) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Thyromimetics for the treatment of fatty liver diseases.
EP1891080A2 (en) * 2005-05-26 2008-02-27 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2006131336A1 (en) * 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
WO2007056210A2 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Diphenylmethane derivatives as inhibitors of leukotriene biosynthesis
EP1965807A4 (en) 2005-11-23 2010-10-27 Epix Delaware Inc S1p receptor modulating compounds and use thereof
US7919519B2 (en) 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
TWI404706B (en) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd Novel thiophene derivatives
JP2009528274A (en) 2006-01-27 2009-08-06 ユニバーシティ オブ バージニア パテント ファンデーション Treatment of neuropathic pain
JP2009526073A (en) 2006-02-09 2009-07-16 ユニバーシティ オブ バージニア パテント ファンデーション Bicyclic sphingosine-1-phosphate receptor analogs
AU2007227274A1 (en) 2006-03-21 2007-09-27 Epix Delaware, Inc. S1P receptor modulating compounds
PL2003132T3 (en) 2006-04-03 2014-10-31 Astellas Pharma Inc Oxadiazole derivatives as S1P1 agonists
EP2258700A1 (en) * 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
JP5140593B2 (en) 2006-08-08 2013-02-06 杏林製薬株式会社 Amino alcohol derivatives and immunosuppressants containing them as active ingredients
CA2659598A1 (en) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Amino phosphate derivative and s1p receptor modulator having same as an active ingredient
JP2009269819A (en) * 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk Amine compound
CA2669104A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
JP2010510249A (en) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション Sphingosine = 1-tetralin analog having 1-phosphate agonist activity
AU2007323557A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
DE102007036068A1 (en) 2007-08-01 2009-02-05 Wacker Chemie Ag Process for the preparation of alkylmethoxymethyltrimethylsilanylmethylamines
AU2008302746B2 (en) 2007-09-20 2014-07-03 Amgen Inc. 1-(4-(benzylbenzamid0) -benzyl) azetidine-3-carboxylic acid derivatives and related compounds as SlP receptor modulators for the treatment of immune disorders
PL2278960T5 (en) 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Dosing regimen for a selective sip1 receptor agonist
MX2011000211A (en) 2008-07-15 2011-03-03 Sanofi Aventis Oxazolopyrimidines as edg-1 receptor agonists.
EP2695615A3 (en) 2008-07-23 2014-04-30 Novartis AG Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
EP2326619B1 (en) 2008-08-01 2019-02-27 Bioxiness Pharmaceuticals, Inc. Methionine analogs and methods of using same
MX2011005954A (en) 2008-12-05 2011-10-11 Astellas Pharma Inc 2h-chromene compound and derivative thereof.
ES2405054T3 (en) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Pyrazole-1,2,4-oxadiazole derivatives as sphingosine-1-phosphate agonists
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
JP2012515787A (en) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー Substituted oxadiazole derivatives as S1P agonists in the treatment of autoimmune and inflammatory diseases
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
US9216972B2 (en) 2009-10-29 2015-12-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
MX2012006028A (en) 2009-11-24 2012-06-19 Allergan Inc Novel compounds as receptor modulators with therapeutic utility.
US8741875B2 (en) 2009-11-24 2014-06-03 Allergan, Inc. Compounds as receptor modulators with therapeutic utility
CN105503882B (en) 2010-03-03 2019-07-05 艾尼纳制药公司 The method for preparing S1P1 receptor modulators and its crystal form
ES2548683T3 (en) 2010-04-23 2015-10-20 Bristol-Myers Squibb Company 4- (5-Isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl) -mandelic acid amides as sphingosine-1-phosphate receptor agonists 1
US8822510B2 (en) 2010-07-20 2014-09-02 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-Oxadiazole compounds
EP2619190B1 (en) 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
EP2635573B1 (en) 2010-11-03 2014-10-01 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
RU2013128328A (en) * 2010-11-23 2014-12-27 Аллерган, Инк. NEW PHOSPHONIC ACIDS AS S1P RECEPTOR MODULATORS
EA034451B1 (en) 2011-02-07 2020-02-10 Байоджен Ма Инк. S1p modulating agents
RU2013150173A (en) 2011-04-14 2015-05-20 Аллерган, Инк. METHYLAMINE DERIVATIVES OF Bicyclic Phenyl as Modulators of Sphingosine-1-Phosphate Receptors
EP2697195A1 (en) 2011-04-14 2014-02-19 Allergan, Inc. Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
US8507686B2 (en) 2011-04-14 2013-08-13 Allergan, Inc. Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
JP2014518554A (en) 2011-04-18 2014-07-31 アラーガン インコーポレイテッド Substituted bicyclic methylamine derivatives as sphingosine-1-phosphate receptor modulators
US9115054B2 (en) 2013-02-21 2015-08-25 Bristol-Myers Squibb Company Tetrahydronaphthalenyl compounds useful as sipi agonists
US20140256945A1 (en) * 2013-03-07 2014-09-11 Allergan, Inc. Phosphonic acid compounds as sphingosine-1-phosphate receptor modulators
US9884087B1 (en) 2013-05-03 2018-02-06 Chan Soon-Shiong Nanthealth Foundation Compositions and methods of improved wound healing
MA40082B1 (en) 2014-08-20 2019-09-30 Bristol Myers Squibb Co New Sphingosine Phosphate Substitution Compound Useful Treatment Disease Rheumatism
PL3242666T3 (en) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
BR112017027656B1 (en) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. CRYSTALLINE HABIT OF SALT-FREE PLATE OF ACID L-ARGININE (R)-2-(7-(4- CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)- 1,2,3,4-TETRA-HYDROCYCLO-PENTA[B ]INDOL-3- IL)ACETIC, PHARMACEUTICAL COMPOSITION THAT COMPRISES IT, ITS USES AND METHOD OF PREPARATION THEREOF
KR102482825B1 (en) 2016-09-02 2022-12-29 브리스톨-마이어스 스큅 컴퍼니 Substituted tricyclic heterocyclic compounds
JP2020500199A (en) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド Methods of treating glycogen storage disease
MX2019009843A (en) 2017-02-16 2020-01-30 Arena Pharm Inc Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations.
MX2019009841A (en) 2017-02-16 2020-01-30 Arena Pharm Inc Compounds and methods for treatment of primary biliary cholangitis.
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
CN113784713A (en) * 2019-01-11 2021-12-10 纳吉斯制药股份有限公司 Leukotriene synthesis inhibitors
CN110724723B (en) * 2019-10-08 2023-04-07 南京信息工程大学 Method for measuring and calculating semi-effective concentration of pollutant ecotoxicity effect
AU2021205465A1 (en) * 2020-01-06 2022-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CN111803484B (en) * 2020-09-04 2021-08-17 郑州大学 The application of otilonium bromide in the preparation of antitumor drugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437165B1 (en) * 2000-08-31 2002-08-20 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69321823T2 (en) * 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-AMINO-1, 3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSIUM
US5585476A (en) * 1994-02-15 1996-12-17 Maclennan; Alexander J. Molecular cloning and expression of G-protein coupled receptors
JPH09278888A (en) * 1996-04-16 1997-10-28 Idemitsu Petrochem Co Ltd Equipment for producing polyarylene sulfide and method for producing polyarylene sulfide using the same
JPH1180026A (en) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd Novel immunosuppressants, methods of use and methods of identification thereof
US6130067A (en) * 1998-05-20 2000-10-10 Smithkline Beecham Corporation Human EDG3sb gene
US6323333B1 (en) * 1999-04-05 2001-11-27 Smithkline Beecham Corporation Mouse EDG1
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437165B1 (en) * 2000-08-31 2002-08-20 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514419B2 (en) 2003-11-19 2009-04-07 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
US8580841B2 (en) 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
US8415484B2 (en) 2008-08-27 2013-04-09 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
US8853419B2 (en) 2010-01-27 2014-10-07 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders

Also Published As

Publication number Publication date
US20050070506A1 (en) 2005-03-31
WO2003061567A2 (en) 2003-07-31
EP1469863A2 (en) 2004-10-27
CA2472680A1 (en) 2003-07-31
AU2003216054B2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
WO2003061567A3 (en) Selective s1p1/edg1 receptor agonists
BRPI0406883A (en) Compound, pharmaceutical composition, method of treating a disorder, and use of a compound
BR0314760A (en) Organic compounds
BR0116370A (en) Compound, pharmaceutical composition, use of a compound, and method of treating an hppar-mediated disease or condition in a patient.
BRPI0415858A (en) compounds of tocopherol-modified therapeutic drugs
BRPI0408784A (en) method to use a compound
KR20090024281A (en) S1 receptor modulator for the treatment of multiple sclerosis
US20040209850A1 (en) Methods of treating pain and compositions for use therefor
IT1241996B (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISORDERS AND METHOD FOR ITS APPLICATION.
BRPI0210886B8 (en) compound, pharmaceutical composition, use of a compound, and, methods of imaging, monitoring the effect of treating a human or animal body with a drug to combat a condition associated with cancer and treating cancer or a related disease in a human or animal body
PT1243263E (en) NEW USE OF A PEPTIDICAL COMPOSITE CLASS FOR THE TREATMENT OF ALODINIA OR OTHER DIFFERENT TYPES OF CHRONIC OR GHOST PAIN
EP2311446A1 (en) Compositions comprising Tramadol and Celecoxib in the treatment of pain
BRPI0408863A (en) compound, pharmaceutical composition, method for treating diseases, and use of a compound.
UA122063C2 (en) PHARMACEUTICAL COMBINATION CONTAINING SELECTIVE S1P1 RECEPTOR AGONIST
AU753079B2 (en) Combination of a selective NMDA NR2B antagonist and a COX-2 inhibitor
BR0316458A (en) Compound, pharmaceutical composition, method of treating or preventing disease, method for enhancing cognition in a healthy patient, and use of a compound
BRPI0410837A (en) compound, pharmaceutical composition, and method for treating or preventing a disease or condition
BRPI0416882A (en) compound, pharmaceutical composition, method of treating a disorder, and use of a compound
EP2050442A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND / OR TREATING BONE DISEASE, FUNCTIONAL FOOD OR DIETARY FOOD CONTAINING THE COMPOSITION, AND PHARMACEUTICAL PREPARATION CONTAINING THE COMPOSITION AS ACTIVE INGREDIENT
BR0314713A (en) Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines.
WO2005004854A3 (en) Use of betaine for treating arteritis
BR112022007348A2 (en) METHODS TO TREAT CONDITIONS RELATED TO THE S1P1 RECEIVER
TW200616644A (en) Medicine for prevention or treatment of diabetes
EA200900269A1 (en) DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES
WO2007104933A8 (en) Chemical compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003216054

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2472680

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10501176

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003731917

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003731917

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP